These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31234236)

  • 21. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Parikh A; Gopalakrishnan S; Freise KJ; Verdugo ME; Menon RM; Mensing S; Salem AH
    Leuk Lymphoma; 2018 Apr; 59(4):871-879. PubMed ID: 28797193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquisition of the recurrent Gly101Val mutation in
    Weiss J; Peifer M; Herling CD; Frenzel LP; Hallek M
    Haematologica; 2019 Nov; 104(11):e540. PubMed ID: 31666345
    [No Abstract]   [Full Text] [Related]  

  • 24. Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.
    Grant S
    Leuk Lymphoma; 2018 Jun; 59(6):1292-1299. PubMed ID: 28838268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial lack of BCL2 in follicular lymphoma: An unusual immunohistochemical staining pattern explained by ongoing BCL2 mutation.
    van den Brand M; Garcia-Garcia M; Mathijssen JJ; Colomo L; Groenen PJ; Serrano S; van Krieken JH
    Pathol Res Pract; 2016 Feb; 212(2):148-50. PubMed ID: 26725534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
    Roulin L; Haioun C; Lemonnier F
    Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):18-9. PubMed ID: 25768998
    [No Abstract]   [Full Text] [Related]  

  • 30. [Follicular non-Hodgkin lymphomas and minimal residual disease].
    Bruno S
    Medicina (B Aires); 2000; 60 Suppl 2():77-82. PubMed ID: 11188937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
    Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
    Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of molecular remission in follicular lymphoma.
    Dührsen U; Hüttmann A; Dürig J
    J Clin Oncol; 2010 Oct; 28(30):e613; author reply e614. PubMed ID: 20713852
    [No Abstract]   [Full Text] [Related]  

  • 38. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL.
    Thangavadivel S; Byrd JC
    Cancer Discov; 2019 Mar; 9(3):320-322. PubMed ID: 30824485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.